Live feed07:30:00·70dPRReleaseLyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell LymphomaLYEL· Lyell Immunopharma Inc.Health CareOriginal source
